-+ 0.00%
-+ 0.00%
-+ 0.00%

WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

Benzinga·09/08/2026 15:38:00
Listen to the news
WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.